All In Biotech

Drug Trial Radar · NCT07908446

Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV

Phase 4, Randomized, Open-label, Non-inferiority Trial of Bictegravir/Lenacapavir Fixed-dose Combination (BIC/LEN FDC) Versus Stable Baseline Regimens (SBR) in Virologically Suppressed (VS) People With HIV (PWH)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2028

Study completion Nov 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the effectiveness and safety of switching to bictegravir/lenacapavir (BIC/LEN) fixed-dose combination (FDC) compared with continuing stable baseline regimens (SBR) in virologically suppressed people with HIV. The primary objective of this study is to evaluate the efficacy of switching to BIC/LEN (75/50 mg) fixed-dose combination (FDC) tablets versus continuing their stable baseline regimen (SBR) in virologically suppressed people with HIV.

Conditions

  • HIV-1 Infection

Interventions

  • BIC/LEN FDCDrug

    Tablet administered orally

  • LenacapavirDrug

    Tablet administered orally

  • SBRDrug

    SBR will include approved ARTs like: integrase strand-transfer inhibitor (INSTI) + 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs), excluding bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), boosted-protease inhibitor (PI) + 2 NRTIs, nonnucleoside reverse transcriptase inhibitor (NNRTI) + 2 NRTIs, or dolutegravir (DTG)/rilpivirine (RPV) or cabotegravir (CAB) + RPV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants With HIV-1 Ribonucleic Acid (RNA) ≥ 50 Copies/mL at Week 24, as Determined by the United States (US) Food and Drug Administration (FDA) Snapshot AlgorithmTime frame: Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.